Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Shattuck Labs, Inc. - Common Stock (NQ:STTK)

5.950 -0.150 (-2.46%)
Streaming Delayed Price Updated: 12:15 PM EDT, May 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Shattuck Labs, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Kaplan Fox & Kilsheimer LLP is Investigating Shattuck Labs, Inc. (STTK) for Potential Securities Law Violations
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Kaplan Fox &amp; Kilsheimer LLP is Investigating Shattuck Labs, Inc. (STTK) for Potential Securities Law Violations
NEW YORK, NY - (NewMediaWire) - October 02, 2024 - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Shattuck Labs, Inc. (“Shattuck” or the “Company”) (NASDAQ:... 
Via TheNewswire.com
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Shattuck Labs Shutters Cancer Program, Lays Off Around 40% Of Its Workforce, Reorganizes Pipeline ↗
Shattuck Labs shifts focus to SL-325 after modest survival improvements in a Phase 1 trial for HR-MDS and TP53m AML. The company plans workforce reductions and expects cash reserves to last into 2027. 
Via Benzinga
News headline image
Shattuck Labs Stock: A Deep Dive Into Analyst Perspectives (7 Ratings) ↗
 
Via Benzinga
News headline image
Assessing Shattuck Labs: Insights From 7 Financial Analysts ↗
 
Via Benzinga
News headline image
Assessing Shattuck Labs: Insights From 6 Financial Analysts ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Shattuck Labs Provides Company Update and Announces SL-325, a First-In-Class Death Receptor 3 (DR3) Antagonist Targeting the TL1A/DR3 Signaling Pathway
From Shattuck Labs, Inc.
Via GlobeNewswire
News headline image
STTK Stock Earnings: Shattuck Labs Misses EPS, Beats Revenue for Q2 2024 ↗
STTK stock results show that Shattuck Labs missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Shattuck Labs Reports Second Quarter 2024 Financial Results and Recent Business Highlights
From Shattuck Labs, Inc.
Via GlobeNewswire
News headline image
Shattuck Labs Announces Participation in Upcoming BTIG Virtual Biotechnology Conference
From Shattuck Labs, Inc.
Via GlobeNewswire
News headline image
Shattuck Labs Announces Addition to Russell 2000® and Russell 3000® Indexes
From Shattuck Labs, Inc.
Via GlobeNewswire
News headline image
Workday To Rally Over 52%? Here Are 10 Top Analyst Forecasts For Thursday ↗
 
Via Benzinga
News headline image
Shattuck Labs Announces Updated Positive Interim Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 in Combination with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid
From Shattuck Labs, Inc.
Via GlobeNewswire
News headline image
Shattuck Labs Announces Orphan Drug Designation Granted by the U.S. Food and Drug Administration (FDA) for SL-172154 for the Treatment of Acute Myeloid Leukemia (AML)
From Shattuck Labs, Inc.
Via GlobeNewswire
News headline image
Shattuck Labs to Host Investor Call and Webcast on Additional Interim Data Presented at the European Hematology Association (EHA) 2024 Congress from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk
From Shattuck Labs, Inc.
Via GlobeNewswire
News headline image
Shattuck Labs to Present Additional Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients at the
From Shattuck Labs, Inc.
Via GlobeNewswire
News headline image
STTK Stock Earnings: Shattuck Labs Beats EPS, Beats Revenue for Q1 2024 ↗
STTK stock results show that Shattuck Labs beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Shattuck Labs Reports First Quarter 2024 Financial Results and Recent Business Highlights
From Shattuck Labs, Inc.
Via GlobeNewswire
News headline image
Shattuck Labs Announces Oral Presentation of Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2024
From Shattuck Labs, Inc.
Via GlobeNewswire
News headline image
Shattuck Labs Announces Participation in Upcoming 23rd Annual Needham Virtual Healthcare Conference
From Shattuck Labs, Inc.
Via GlobeNewswire
News headline image
Shattuck Labs Announces Appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D., to its Board of Directors
From Shattuck Labs, Inc.
Via GlobeNewswire
News headline image
Shattuck Labs Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights
From Shattuck Labs, Inc.
Via GlobeNewswire
News headline image
Shattuck Labs Announces Participation in Upcoming March Conferences
From Shattuck Labs, Inc.
Via GlobeNewswire
News headline image
Shattuck Labs Enters into Strategic Collaboration and License Agreement with Ono Pharmaceutical to Generate Bifunctional Fusion Proteins for the Treatment of Autoimmune and Inflammatory Diseases
From Shattuck Labs, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2024
From Shattuck Labs, Inc.
Via GlobeNewswire
News headline image
Why RxSight Shares Are Trading Higher By 20%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
Shares of RxSight, Inc. (NASDAQ: RXST) rose sharply during Monday’s session after the company issued preliminary FY23 and FY24 revenue guidance above estimates. Also, Needham maintained a Buy rating on... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.